## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG 4.06 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($655.13)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Precision Trading with Idexx Laboratories Inc. (IDXX) Risk Zones**
- Source: Stock Traders Daily | 20251229T061600 | Somewhat-Bearish | Relevance: 100%
- This article discusses precision trading strategies for Idexx Laboratories Inc. (IDXX) based on AI-generated risk zones. It highlights a weak near and mid-term sentiment but a strong long-term outlook, presenting specific entry, target, and stop-loss levels for position, momentum, and risk-hedging strategies. The analysis emphasizes an exceptional risk-reward short setup with a 25.9:1 ratio.

**2. Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?**
- Source: Yahoo Finance Singapore | 20251229T150825 | Bullish | Relevance: 100%
- IDEXX Laboratories (IDXX) stock has outperformed its Medical sector peers this year, gaining 66.5% compared to the sector's average of 8.2%. The company, holding a Zacks Rank #2 (Buy), also shows strong analyst sentiment with a 2.5% increase in its full-year earnings estimate over the past 90 days. Artivion (AORT) is another medical stock demonstrating strong performance within the same industry group as IDEXX.

**3. Swedbank AB Purchases 2,107 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251227T104920 | Somewhat-Bullish | Relevance: 100%
- Swedbank AB increased its stake in IDEXX Laboratories, Inc. by 5.9%, acquiring an additional 2,107 shares in the third quarter, bringing its total holdings to 37,832 shares valued at approximately $24.17 million. Meanwhile, IDEXX EVP Nimrata Hunt sold 9,425 shares, reducing her position by over 30%. Analysts maintain a "Moderate Buy" rating for IDEXX, with a consensus target price of $763.50, following strong Q3 earnings and positive FY2025 guidance.

**4. IDEXX Laboratories, Inc. $IDXX Shares Acquired by Beacon Investment Advisory Services Inc.**
- Source: MarketBeat | 20251227T080752 | Bullish | Relevance: 100%
- Beacon Investment Advisory Services Inc. increased its stake in IDEXX Laboratories (NASDAQ:IDXX) by 15.7% in the third quarter, now owning 56,241 shares valued at $35.93 million. This makes IDEXX its 16th largest position, representing about 0.07% of the company's outstanding stock. IDEXX recently beat quarterly earnings expectations, and analysts have set a "Moderate Buy" consensus rating with an average target price of $763.50.

**5. BankPlus Trust Department Purchases 1,830 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251228T080819 | Bullish | Relevance: 99%
- BankPlus Trust Department significantly increased its stake in IDEXX Laboratories, purchasing 1,830 additional shares to bring its total holdings to 1,962 shares, valued at approximately $1.254 million. The company recently exceeded Q3 earnings expectations, reporting an EPS of $3.22 and revenue of $1.11 billion, leading to several analysts raising their price targets and a consensus "Moderate Buy" rating. Despite bullish institutional activity, an EVP recently sold a substantial portion of her shares, reducing her position by over 30%.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.1x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.06 signals overvaluation risk, limited margin of safety. Forward P/E 47.7x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $55.0B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.06 |
| Forward P/E | 47.7 |
| Current P/E | 53.3 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.4% to -1.6% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-3.47), momentum weakening. RSI neutral at 44. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.64% (CS: 21) | Neutral |
| RSI_14 | 43.8 | Neutral |
| MACD Histogram | -3.47 | Bearish |
| vs SMA20 | 0.978x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.188x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $687.89
- **Stop Loss:** $655.13 (4.8% risk)
- **Target:** $720.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 42
- **Position Value:** $28,891.38
- **Portfolio %:** 28.89%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*